| Code | CSB-RA005983MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Verekitug, targeting CRLF2 (Cytokine Receptor-Like Factor 2), a type I cytokine receptor that forms a heterodimeric complex with IL7Rα to create the thymic stromal lymphopoietin (TSLP) receptor. CRLF2 plays a critical role in lymphoid development and immune regulation through TSLP signaling, which activates JAK-STAT and PI3K-AKT pathways. Aberrant CRLF2 expression and genetic alterations, including CRLF2 rearrangements and F232C mutations, are frequently observed in high-risk B-cell acute lymphoblastic leukemia (B-ALL), particularly in Philadelphia chromosome-like ALL and Down syndrome-associated ALL, where they contribute to leukemogenesis and poor clinical outcomes.
Verekitug represents a therapeutic antibody designed to target CRLF2-overexpressing malignancies by blocking TSLP-mediated signaling. This biosimilar antibody provides researchers with a valuable tool for investigating CRLF2 biology, exploring mechanisms of TSLP receptor activation, studying CRLF2-driven oncogenic pathways, and evaluating potential therapeutic interventions in CRLF2-related hematologic malignancies and immune disorders.
There are currently no reviews for this product.